Glycerol Izotóniás Nacl Oldatban Teva

Glycerol Izotóniás Nacl Oldatban Teva is an intravenous solution for injection that contains glycerol as the sole active ingredient. The product is supplied in a sterile liquid form, with the glycerol concentration not specified on the label. It is marketed in the European Union and is classified as an excipient and solvent used to adjust tonicity and serve as a vehicle for other parenteral medicines.

Glycerol Izotóniás Nacl Oldatban Teva is primarily employed as a solvent and tonicity-adjusting agent in parenteral preparations.

- Dilutes or reconstitutes lyophilized injectable drugs for intravenous administration. - Maintains isotonicity of intravenous solutions containing active pharmaceutical ingredients. - Serves as a carrier for drugs that require a non‑ionic, water‑soluble medium. - Provides a compatible medium for mixing with electrolytes or other infusion components. - Used in clinical settings to stabilize the pH of intravenous formulations. - Facilitates safe intravenous infusion when combined with compatible medications.

Intravenous glycerol solutions can cause a range of reactions, from mild, transient effects to rare but serious events that require medical attention.

Common: - Mild pain, burning, or irritation at the injection site. - Transient flushing, warmth, or feeling of heat during infusion. - Temporary rise in blood glucose concentrations, especially in diabetic patients. - Slight shifts in serum sodium or chloride levels due to isotonic adjustment. - Headache or mild dizziness during or shortly after administration.

Serious: - Anaphylactic or severe hypersensitivity reactions, including rash, swelling, and respiratory distress. - Marked hypotension or circulatory collapse, potentially requiring vasopressor support. - Acute kidney injury or worsening renal function, particularly in patients with pre‑existing renal disease.

When using Glycerol Izotóniás Nacl Oldatban Teva, clinicians should observe several precautionary measures to ensure patient safety and product integrity.

- Verify solution clarity, absence of particles, and correct labeling before administration. - Assess patient history for glycerol hypersensitivity or prior allergic reactions. - Monitor blood glucose and electrolyte levels during and after infusion, especially in diabetic or renal patients. - Adjust infusion rate according to patient tolerance and clinical guidelines. - Avoid use in patients with severe dehydration or uncontrolled hyperosmolar states. - Store the product according to manufacturer instructions, protecting it from light and extreme temperatures.

Glycerol solutions may interact with other intravenous agents, requiring careful consideration of compatibility and patient condition.

Avoid: - Co‑administration with highly hypertonic or acidic solutions that may precipitate active drugs. - Mixing with calcium‑containing solutions that could cause precipitation. - Simultaneous infusion with other high‑volume osmotic agents, increasing risk of fluid overload. - Mixing with solutions containing high concentrations of potassium, which may cause electrolyte imbalance.

Use with caution: - Concurrent use with insulin or oral hypoglycemics; monitor glucose closely. - Administration alongside nephrotoxic drugs; observe renal function. - Use with vasopressors or antihypertensives; watch for additive blood pressure effects. - Combination with other solvents (e.g., ethanol) may alter tolerability. - Mixing with other compatible IV fluids should be performed under aseptic conditions.